Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan With or Without Neratinib in HER2-positive Breast Cancer With Brain Metastasis
NCT07152782Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Aug 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in breast cancer, sponsored by Fudan University. Started Sep 2025; status: recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07152782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152782.